Dupilumab for treatment-refractory prurigo nodularis

J Dtsch Dermatol Ges. 2020 Jun;18(6):618-624. doi: 10.1111/ddg.14107. Epub 2020 May 29.

Authors

Bálint Kovács¹, Ellen Rose¹, Nadine Kuznik¹, Iakov Shimanovich¹, Detlef Zillikens^{1

2}, Ralf J Ludwig^{2

3}, Diamant Thaçi^{2

4}

Affiliations

¹ Department of Dermatology, University of Lübeck, Lübeck, Germany.
² Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany.
³ Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
⁴ Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.

PMID: 32469446
DOI: 10.1111/ddg.14107

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Humans
Prurigo / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
dupilumab